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Abstract 
 
Although cholesterol plays various important roles in the body, when overconsumed, it 
causes atherosclerosis and results in ischemic heart disease. On the other hand, dietary fish 
oils contain n-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), which prevent ischemic heart disease. This effect of n-3 fatty acids mainly 
results from the combined effects of inhibiting lipogenesis via a decrease of the mature 
form of sterol regulatory element-binding proteins (SREBPs) and stimulating fatty acid 
oxidation, via peroxisome proliferator-activator receptor (PPAR) α activation in the liver. 
In this study, we examined the interactive effects on lipid metabolism of dietary 2% 
cholesterol (w/w) and 20 or 50% energy fish oil. In a safflower oil diet with 2% 
cholesterol, hepatic lipids accumulated. On the other hand, hepatic lipids did not 
accumulate in the fish oil diets with cholesterol. Furthermore, in the groups with fish oil 
energy ratios of 20%, the negative feedback control of cholesterol affected SREBP-2, and 
the actions of fish oil and cholesterol were equivalent, but this was not observed in the 
cases with fish oil energy ratios of 50%. The results of this study suggest that differences 
in lipid accumulation in the body are due to differences in lipid source and energy ratios 
which differentially impact the control of transcription factors by cholesterol. 
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1. Introduction 
Atherosclerotic diseases such as coronary artery disease and cerebral infarction account 
for the major causes of death in many countries. It has been determined that hyper 
low-density lipoprotein (LDL) cholesterolemia is closely associated with these diseases [1]. 
On the other hand, it is known that high-density lipoprotein (HDL) cholesterol level shows 
negative correlation with development of coronary artery disease [2]. This means that 
decreases in LDL cholesterol levels and increases in HDL cholesterol levels in the blood are 
important for prevention of coronary artery disease. 
Cholesterol is one of the components of animal cell membranes, and a precursor for the 
synthesis of bile acid, steroid hormone, and vitamin D. Much of the cholesterol produced in 
the body is synthesized from acetyl-CoA in the liver, and is eventually excreted as 
cholesterol in bile or bile salt. Cholesterol and phytosterol in the inner cavity of the small 
intestine are imported in to epithelial cells by Niemann-Pick C1 like-1 (NPC1L1) protein on 
the brush border of epithelial cells of the small intestine [3], and cholesterol is released in to 
the lymph duct as chylomicron. On the other hand, phytosterol is considered to be drawn 
from epithelial cells to the inner cavity of the small intestine together with a cholesterol by a 
heterodimer of ATP-binding cassette transporter (ABC) G5 and G8[4].  It is known that 
cholesterols, including 22- and 24-hydroxy cholesterol, act as ligands for liver X receptor 
(LXR) α[5]. LXRα, a nuclear receptor, forms a heterodimer together with the retinoid X 
receptor (RXR), and combines with LXR element (LXRE) at the promoter of target genes to 
control transcription. The target genes of LXR include cholesterol 7α-hydroxylase 
(CYP7A1), ABCA1, ABCG1, and sterol regulatory element-binding proteins (SREBPs), 
genes which are highly involved in cholesterol metabolism [6, 7]. 
It has been reported that fish oil, which includes high percentages of n-3 polyunsaturated 
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fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), decreases 
the risk of cardiovascular disease by decreasing blood triglyceride concentrations [8]. It is 
known that such effects of fish oil are caused by a combination of inhibition of lipogenesis 
and increased in fatty acid oxidation, mainly in the liver [9-11]. In the regulation of genes 
related to lipogenesis, SREBPs, which control cholesterol levels in cells as a function of 
their transcriptional levels, are involved [12]. SREBPs form a complex with SREBP 
cleavage-activating protein (SCAP), and are localized on the endoplasmic reticulum 
membrane, forming a hairpin structure. When intracellular cholesterol levels decrease, the 
complex of SCAP and membrane-bound precursor SREBP is transferred to the Golgi body, 
and becomes active after a two-step cleavage event by site-1 protease (S1P) and site-2 
protease (S2P). The activated SREBP is transferred into the nucleus, and binds to sterol 
regulatory elements (SREs) in the gene promoter to facilitate the transcription [13,14]. 
SREBPs have three isoforms, -1a, -1c, and -2. It was reported that SREBP-1a and -1c 
mainly activate the transcription of fatty acid synthesis-related genes, such as fatty acid 
synthase (FAS), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD), while 
SREBP-2 mainly activates the transcription of cholesterol synthesis-related genes, such as 
the HMG-CoA reducing enzyme, the HMG-CoA synthetic enzyme and the LDL receptor 
[10,15,16]. 
Based on the results of many studies, it is known that fish oil inhibits lipid synthesis by 
decreasing the expression of genes such as SREBP, FAS, ACC, and SCD, in the liver. In 
addition, it is known that fish oil may induce fatty acid oxidation by increasing the 
expression of genes, such as acyl-CoA oxidase (AOX), acetyl-CoA synthetase (ACS), and 
uncoupling protein (UCP)-2 via peroxisome proliferator-activated receptor (PPAR) α 
activation [17-20]. 
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To investigate effective concentrations of fish oil that will improve cholesterol 
metabolism in the liver, groups of fish oil with lipid energy ratios of 20% and 50% that are 
found in high cholesterol diets in which 2% cholesterol was added, were prepared in this 
study. The lipid energy ratio of 20% was considered to be a ratio that can be taken in an 
ordinary diet, while the 50% ratio has often been used in past studies on high lipid diets, and 
was considered to be a condition in which the effects of fish oil would be clearly observable 
in this study. 
 
 
2. Materials and Methods 
2.1. Diet compositions 
The composition of diets used in this study is shown in Table 1. We prepared diets that we 
classified as the SO group, in which lipid energy ratio was set to be 20% with safflower oil 
used as the fat source; the 20FO group, in which the ratio was set to be 20% with fish oil 
used as the fat source; and the 50FO group, in which the ratio was set to be 50% with fish 
oil used as the fat source. In addition, 2% cholesterol was added to individual groups to 
prepare the SO/CH, 20FO/CH, and 50FO/CH groups. Casein, sucrose, β-starch, AIN-93G 
mineral mixture, AIN-93G vitamin mixture, and cellulose powder were obtained from 
Oriental Yeast Co. Ltd. (Tokyo, Japan), and L-cystine, t-butylhydroquinone, and cholesterol 
were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
 
2.2. Animals 
Five 8-week-old C57BL/6 female mice (Tokyo Laboratory Animals Science Co., Ltd., 
Japan) were included in each group. Breeding was performed at the Josai University Life 
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Science Center with conditions of light-dark cycle at 12-hour intervals (light: 7:00 - 19:00), 
room temperature of 23 ± 2°C, and humidity of 55 ± 10%. Feed and water were freely 
provided, and the feed was changed at 11:00 every day and residual quantity was measured. 
Preliminary breeding was performed for 1 week (including a quarantine period) before 
commencement of the 8-week feeding. All animal studies were performed in accordance 
with the “Standards Relating to the Care and Management of Experimental Animals” 
(Notice No. 6 of the Office of Prime Minister dated March 27, 1980) and the guidelines of 
Institutional Animal Care and Use Committee at the Josai University Life Science Center. 
 
2.3. Collection of blood and tissue samples 
At the end of the experiments, mice were anestheticized with injected pentobarbital 
sodium (Dainippon Pharmaceutical Co., Ltd., Japan), and animal X-ray CT (La Theta LCT 
100, ALOKA Co., Ltd., Japan) was performed to measure body composition, which 
determined the fat level. After weight measurement, blood sampling with EDTA-2Na from 
tail vein, and assay of blood glucose level using a blood glucose reader (Ascensia Breeze, 
Bayel Medical), autopsy was performed. After blood sampling from the inferior vena cava 
and removal of the liver, photographs of the liver were taken using a digital camera. Part of 
the removed liver was fixed with 10% neutral buffered formalin (Wako Pure Chemical 
Industries, Ltd.), and Kotobiken Medical Laboratories, Inc. (Tokyo, Japan) performed 
Hematoxylin eosin staining for histopathological examination. Fat tissues (white adipose 
tissues around the uterus and brown adipose tissues) were removed for weight measurement. 
Sample blood was centrifuged (3,000 rpm, 4°C, 10 min.) to separate plasma, and frozen at 
-80°C for storage until analysis. Removed organs were frozen with liquid nitrogen and 
stored at -80°C. 
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2.4. Measurement of lipid in plasma and liver 
Hepatic lipid was extracted from approximately 100 mg liver tissue from individual mice 
in accordance with the method of Folch et al. [21]. For the measurements of total cholesterol 
and triglyceride in the liver, Cholesterol E-Test Wako and Triglyceride E-Test Wako (Wako 
Pure Chemical Industries, Ltd.) were used, respectively. Measurement of total cholesterol 
and triglyceride were performed using the same test kits. For the measurement of plasma 
HDL-cholesterol, HDL-Cholesterol E-Test Wako (Wako Pure Chemical Industries, Ltd.) 
was used. 
 
2.5. Measurement of mRNA in the liver 
Total RNA was extracted from liver tissue of each mouse using Trizol (Invitrogen Co.) in 
accordance with the manufacturer’s protocol. The measurement of mRNA levels by 
Real-time PCR was performed using the ABI Prism 7500 Sequence Detection System 
(Applied Biosystems Co.). mRNA were amplified with QuantiTect SYBP Green (QIAGEN, 
Hilden, Germany), Quantitect RT Mix, and using specific primers optimized at 100% by the 
manufacturer (Sigma-Aldrich Japan, Tokyo, Japan). The thermal cycling conditions were as 
follows: reverse transcription at 50°C for 30 min, initial denaturation at 95°C for 15 min 
plus 40 cycles at 94°C for 15 s, 55°C for 30 s and at 72°C for 1 min. The PCR primers used 
were as follows: SREBP-1c, forward primer, GGCCGAGATGTGCGAACT and reverse 
primer, TTGTTGATGAGCTGGAGCATGT; 
 Insig-1, forward primer, TCACAGTGACTGAGCTTCAGCA and reverse primer, 
TCATCTTCATCACACCCAGGAC; 
Insig-2a, forward primer, CCCTCAATGAATGTACTGAAGGATT and reverse primer, 
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TGTGAAGTGAAGCAGACCAATGT; 
 SREBP-2, forward primer, GCGTTCTGGAGACCATGGA and reverse primer, 
ACAAAGTTGCTCTGAAAACAAATCA;  
FAS, forward primer, TCACCACTGTGGGCTCTGCAGAGAAGCGAG and reverse 
primer TGTCATTGGCCTCCTCAAAAAGGGCGTCCA;  
SCD-1, forward primer, CCGGAGACCCCTTAGATCGA and reverse primer, 
TAGCCTGTAAAAGATTTCTGCAAACC;  
HMG-CoA reductase, forward primer, CTTGTGGAATGCCTTGTGATTG and reverse 
primer, AGCCGAAGCAGCACATGAT;  
LDL-receptor, forward primer, AGGCTGTGGGCTCCATAGG and reverse primer, 
TGCGGTCCAGGGTCATCT;  
PPARα, forward primer, GTGGCTGCTATAATTTGCTGTG and reverse primer, 
GAAGGTGTCATCTGGATGGTT;  
AOX, forward primer, TCAACAGCCCAACTGTGACTTCCATTA and reverse primer, 
TCAGGTAGCCATTATCCATCTCTTCA; 
 UCP-2, forward primer, GTTCCTCTGTCTCGTCTTGC and reverse primer, 
GGCCTTGAAACCAACCA; 
 CYP7A1, forward primer, CTGTGTTCACTTTCTGAAGCCATG and reverse primer, 
CCCAGGCATTGCTCTTTGAT; 
 CYP8B1, forward primer, TTCGACTTCAAGCTGGTCGA and reverse primer, 
CAAAGCCCCAGCGCCT. 
 
2.6. Statistical analysis 
A one-way analysis of variance (ANOVA) was performed on the data, and comparison 
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among groups used Fisher’s PLSD method. Differences were considered significant when 
P<0.05. 
 
 
3. Results 
3.1. Body weight and tissue weight 
Although final weights increased in all groups, increases in body weight (final weight − 
initial weight) were significantly less in the 20FO/CH and 50FO groups, compared with the 
SO group. The liver weight significantly decreased in the 20FO group, compared with the 
SO group, regardless of the addition of cholesterol. No large difference in the weight of 
white adipose tissues around the uterus and brown adipose tissues between the groups was 
observed (Table 2). 
 
3.2. Liver appearance and tissue histology 
To investigate the effects of fish oil and cholesterol on lipid accumulation in the liver, the 
appearance and tissue specimens of the liver were compared (Fig. 1). Although the liver 
weight in the SO/CH group was similar to that in the SO group, the liver size was enlarged, 
and the entire surface and inside of the liver changed color. Tissue specimens of the SO/CH 
group showed deposition of many lipid droplets over the entirety of the hepatic cells. 
However, such deposition of lipid droplets was not observed in the fish oil groups, 
regardless of the addition of cholesterol. 
 
3.3. Assessment of abdominal fat tissues using X-ray CT 
Although visceral fat (pink parts) in the SO/CH group was clearly larger than in the SO 
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group, visceral fat in the 20FO and 50FO groups decreased, and even in the 20FO/CH and 
50FO/CH groups, in which fish oil and cholesterol were concomitantly used, no increase of 
visceral fat was observed. A similar tendency was observed regarding subcutaneous fat 
(yellow parts) (Fig. 2). A graph of the digitalized X-ray CT images is shown in Fig. 2. 
 
3.4. Plasma and hepatic lipid levels 
To examine the effects of dietary fish oil and cholesterol on lipid metabolism in the body, 
plasma and hepatic lipid levels were measured, and the results are shown in Fig. 1 and Fig. 3. 
Although total cholesterol level in plasma significantly decreased in the 20FO group, 
compared with the SO group, the level significantly increased in the 20FO/CH and 
50FO/CH groups, compared with the 20FO and 50FO groups, respectively. Although 
plasma HDL-cholesterol level tended to decrease in the SO/CH group, levels in the 
20FO/CH and 50FO/CH groups significantly increased. These data, suggested that increases 
in total plasma cholesterol in the 20FO/CH and 50FO/CH groups were caused by increased 
HDL cholesterol. As for hepatic lipid levels, it was found that triglyceride levels and total 
cholesterol levels in the SO/CH group increased 2.1-fold and 9-fold compared to the SO 
group, respectively. On the other hand, no large increase was observed in total cholesterol 
and triglyceride levels in the 20FO/CH and 50FO/CH groups, in which cholesterol was used 
in addition to fish oil (Fig. 1). 
 
3.5. Hepatic expression levels of genes involved in lipid metabolism 
Expression levels of SREBPs, transcription factors that regulate lipid metabolism-related 
genes, and SREBP target genes, are shown in Table 3. Although SREBP-1c mRNA level 
tended to decrease in the 50FO groups, compared with the SO group, the decrease in the 
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expression caused by fish oil was abrogated when cholesterol was added. Insig-1 and 
Insig-2a mRNA, which strongly response to nutrients and insulin, significantly decreased in 
the 20FO and 50FO groups, compared with the SO group. The tendency for further decrease 
was observed in the 20FO/CH and 50FO/CH groups, in which cholesterol was added. On 
the other hand, SREBP-2 mRNA expression levels tended to decrease in the 50FO group, 
compared with the SO group, and the level significantly decreased when cholesterol was 
added. Such decreases were observed not only in the fish oil groups, such as the 20FO/CH 
and 50FO/CH groups, but also in the SO/CH group. 
The level of FAS mRNA, a target gene of SREBP-1c, decreased in the 20FO and 50FO 
groups by 22% and 8%, respectively. Regarding the effects of cholesterol on FAS mRNA 
expression, it was found that the expression level in the SO/CH and 20FO/CH groups 
decreased by more than 50%, compared with the SO and 20FO groups, respectively, but no 
difference was observed between the 50FO/CH and 50FO groups. Although mRNA level of 
SCD-1 decreased dose-dependently in the 20FO and 50FO groups, as seen in FAS, no 
further decrease was observed for SCD-1 when cholesterol was added. Although both FAS 
and SCD-1 are target genes of SREBP-1c, these findings suggest that these genes might be 
controlled by separate mechanisms when cholesterol is added. 
The expression of HMG-CoA reductase mRNA, a gene involved in cholesterol synthesis, 
significantly decreased in the 20FO and 50FO groups, compared with the SO group, and no 
further decrease was observed when cholesterol was added. 
The expression of PPARα mRNA, a transcription factor for fatty acid oxidation-related 
genes, increased in the fish oil groups, regardless of the addition of cholesterol. The mRNA 
expression of AOX, a target gene of PPARα involved in fatty acid oxidation, and UCP-2, 
involved in heat production, significantly increased in the 20FO and 50FO groups, 
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compared to the SO group. However, although no changes were observed in AOX mRNA 
expression when cholesterol was added, UCP-2 mRNA expression decreased. 
In the mRNA expression of CYP7A1 and CYP8B1, genes involved in bile acid synthesis, 
CYP7A1 tended to increase in the 50FO group and CYP8B1 significantly increased in the 
20FO and 50FO groups, compared with the SO group. The effects of cholesterol differed 
between the two genes: the expression of CYP7A1 mRNA clearly increased when 
cholesterol was added, compared with the groups in which only fish oil was used, while no 
such increase was observed in the expression of CYP8B1 mRNA when cholesterol was 
added. Furthermore, the expression of CYP8B1 mRNA tended to decrease in the 50FO 
group, when cholesterol was added. 
 
 
4. Discussion 
  In this study, the body weight gain was small in groups where fish oil was used as the 
lipid source, compared with the SO group. The liver weight and the ratio of the liver to body 
weight were significantly decreased in the 20FO group, but these values in the 50FO group 
were similar to those in the SO group, with a lipid energy ratio of 20%. In some studies on 
physiological action of fish oil, it has been reported that liver weight would increase when 
liver peroxisomes increased [21], but no significant increase was observed in this study. On 
the other hand, the effect of cholesterol was largest in the liver of the safflower oil groups. 
The liver in SO/CH group showed an increase in size and a dramatic change in color. 
Hepatic tissue specimens also indicated deposition of many lipid droplets distributed 
throughout the hepatic cells. Such deposition of lipid droplets caused by addition of 
cholesterol was not seen in groups where fish oil was used as the lipid source, and this 
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confirmed that differences in oil type have a large effect on cholesterol metabolism in the 
liver. While hepatic triglyceride and total cholesterol levels were extremely high in the 
SO/CH group, no large increase due to cholesterol was observed in the 20FO/CH and 
50FO/CH groups, and this finding was reflected in the histopathological results. In addition, 
the accumulation of cholesterol in the liver was similar in the 20FO/CH and 50FO/CH 
groups which suggest that the effects of fish oil on inhibition of cholesterol accumulation 
would be sufficient, even in cases with energy ratios of 20%. 
The main catabolic pathway of cholesterol is the synthesis of bile acid in the liver. The 
synthetic pathway of bile acid is controlled by CYP7A1, which is induced by LXR [4]. In 
this study, CYP7A1 mRNA level in the liver increased in the 50FO group, compared with 
the SO group, and increases were seen in all groups when cholesterol was added. It is 
speculated that CYP7A1 mRNA level is increased by the addition of cholesterol due to 
negative feedback mechanisms which maintain the homeostasis of cholesterol in the body. 
On the other hand, it is known that cholic acid is the major primary bile acid, and CYP8B1 
is involved in the enzymes of cholic acid synthesis [23, 24]. Several studies have reported 
that cholesterol feeding regulates the expression of CYP7A1 and CYP8B1 genes in different 
directions. We also observed that the expression of CYP8B1 mRNA suppressed when 
cholesterol was added in the 50% fish oil energy ratios.  
In the SO/CH group, high cholesterol levels in the blood were prevented by an increase in 
the catabolism of cholesterol, but, as a result, high levels of lipid accumulated in the liver, 
causing fatty liver and increased visceral fat and subcutaneous fat in the abdomen. On the 
other hand, in the 20FO/CH and 50FO/CH groups in which fish oil and cholesterol were 
used concomitantly, almost no accumulation of lipid was observed in hepatic cells, and 
abdominal fat was also decreased. Increases in catabolism of cholesterol and other factors 
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are speculated to account for these findings. Further investigation is required on this matter. 
Comparison of visceral fat and subcutaneous fat levels based on analysis of X-ray CT 
images showed that visceral fat and subcutaneous fat in all fish oil groups tended to decrease, 
regardless of the addition of cholesterol. The mRNA levels of SREBP-1c and -2, decreased 
in fish oil groups, compared with safflower oil group. The mRNA level of FAS and SCD-1, 
also decreased in the fish oil groups, regardless of the addition of cholesterol. Fish oil 
inhibited lipid synthesis even when cholesterol was added, which suggests that such an 
effect is similar for lipid energy ratios of 20% and 50%. Regarding fish oil to inhibition of 
lipid accumulation, it is known that target genes of SREBP-1c decrease when expression of 
SREBP-1c is decreased [8, 9], and we obtained similar results in this study. PPARα mRNA 
is increased by highly unsaturated fatty acid and fibrate drugs that decrease neutral fat [18], 
and we saw increases in PPARα mRNA in fish oil groups, regardless of addition of 
cholesterol. Also, AOX, and UCP-2 mRNA, increased in the fish oil groups. Our data 
indicate that fish oil may effectively inhibit lipid accumulation in the body both by 
inhibiting fatty acid synthesis and facilitating oxidation of fatty acid. On the other hand, 
when cholesterol was concomitantly used with fish oil, both might have affected fatty acid 
metabolism and cholesterol metabolism. In this study, it was shown that AOX and UCP-2 
mRNA expression in the liver increased in both the cases with lipid energy ratios of 20% 
and 50% in groups where only fish oil was used. However, when cholesterol was added, 
differences in expression of AOX and UCP-2 mRNA were seen. While the expression level 
of AOX mRNA was not changed by cholesterol, UCP-2 mRNA decreased when cholesterol 
was added. Due to the SRE in the promoter region of the UCP-2 gene [25, 26], it has been 
hypothesized that the expression level of UCP-2 mRNA might decrease when SREBP-2 
mRNA decreased in a state with excessive cholesterol. HMG-CoA reductase mRNA 
15 
 
decreased in the 20FO and 50FO groups, compared with the SO group, and a tendency of 
further decrease was observed in the 20FO/CH group. On the other hand, in the 50FO group, 
no further decrease was observed when cholesterol was added. There is a report that shows 
fish oil may decrease mRNA levels of cholesterol synthesis related genes through a decrease 
in SREBP-2 [9]. In the present study, expressions of genes controlled by SREBP-2 were 
inhibited by the combined actions of fish oil and cholesterol in the 20FO/CH group, while 
expressions of these genes did not show additional decrease in the 50FO/CH group 
compared to 50FO group. This suggests that the effect of fish oil was larger in the 50FO/CH 
group than the 20FO/CH group. Based on these data, it might be difficult to observe the 
changes caused by cholesterol when the concentration of fish oil was high. 
When the intracellular concentration of cholesterol was increased by adding cholesterol to 
the diet, lipid synthesis decreased along with the expression of SREBP’s target genes. 
However, when cholesterol was added to a group in which safflower oil was used as the 
lipid source, almost no decrease in lipid synthesis was observed, and significant lipid 
accumulation in hepatic cells and increases of white adipose tissue were observed. In 
contrast, when cholesterol was added to a group in which fish oil was used as the lipid 
source, SREBPs were affected by negative feedback, resulting in inhibition on lipid 
accumulation in hepatic cells, and no increase was observed in abdominal visceral fat and 
subcutaneous fat tissues. Such changes were larger in the cases with fish oil energy ratios of 
20% than in the cases with ratios of 50%. 
In this study, it was shown that lipid accumulation in tissues was inhibited by fatty acid 
degradation, which was facilitated by inhibited lipid synthesis through a decrease in SREBP 
expression and increased expression of fatty acid oxidation-related genes, such as AOX and 
UCP-2, both in the groups with fish oil energy ratios of 20% and 50%, regardless of addition 
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of cholesterol. The results of this study suggest that differences in lipid accumulation in the 
body are due to differences in lipid source and energy ratios which differentially impact the 
control of transcription factors by cholesterol. 
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Legends for figures and tables 
Fig. 1.  
Liver appearance, tissue histology and lipid levels of 16-week-old female mice.  
Liver appearance (A) , H&E-stained liver sections (B), total cholesterol (TC) (C), and 
triglycerides (TG) (D) in mice fed SO, SO/CH, 20FO, 20FO/CH, 50FO, and 50FO/CH for 8 
weeks. Values represent means ± S.D. (n=4-5). Means with different letters are different at 
the p<0.05 level by Fisher’s protected least significant difference (PLSD) test. 
 
Fig. 2.  
CT-based fat tissues composition analysis of 16-week-old female mice.  
Representative X-ray CT images of mice fed SO, SO/CH, 20FO, 20FO/CH, 50FO, and 
50FO/CH for 8 weeks, at the L3 level (A). The areas indicated with pink, yellow, and 
light-blue are visceral fat, subcutaneous fat, and muscle, respectively. CT-estimated amounts 
of visceral fat (B) and subcutaneous fat (C) in the abdominal area of L2–L4. Values represent 
means ± S.D. (n=4-5). Means with different letters are different at the p<0.05 level by 
Fisher’s protected least significant difference (PLSD) test. 
 
Fig. 3.  
Blood glucose and plasma lipid levels of 16-week-old female mice.  
Blood glucose (A), triglyceride (TG) (B), Total cholesterol (TC) (C), and high-density 
lipoprotein cholesterol (HDL-C) (D) in mice fed SO, SO/CH, 20FO, 20FO/CH, 50FO, and 
50FO/CH for 8 weeks. Values represent means ± S.D. (n=4-5). Means with different letters 
are different at the p<0.05 level by Fisher’s protected least significant difference (PLSD) test. 
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Table 1  
Composition of the experimental diets 
*All ingredients are in grams per 100 g of diet. 
**Vitamin mix and mineral mix were based on the AIN-93G formation. Vitamin mix 
substituted 0.25% sucrose for choline bitartrate. 
 
Table 2  
Body weight, liver weight and adipose weight of 16-week-old female mice 
Values represent means ± S.D. (n=4-5). Means with different letters are different at the 
p<0.05 level by Fisher’s protected least significant difference (PLSD) test. 
 
Table 3  
The mRNA expression of SREBP-1c and other lipogenic genes 
The mRNA expression levels in livers of mice fed SO, SO/CH, 20FO, 20FO/CH, 50FO, and 
50FO/CH for 8 weeks. Values represent means ± S.D. (n=4-5). Means with different letters 
are different at the p<0.05 level by Fisher’s protected least significant difference (PLSD) test. 
 
 






